What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.
A look at Haemonetics’s Q1 2019 estimates
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software. The services portfolio includes consulting services and software services.
The above chart compares EPS and revenue since Q1 2018 and estimates for fiscal Q1 2019. Haemonetics is set to release its Q1 2019 earnings on August 7. Wall Street analysts estimate the company will post EPS of $0.42 on revenues of $219.9 million in Q1 2019.
Q1 2019 revenue estimates
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018. The growth in revenues is expected to be driven by an increase in revenues from plasma centers and hospitals, while revenues from blood centers are expected to decrease during the quarter. The revenues from hospitals are expected to be driven by an increase in revenues from hemostasis management.
Wall Street analysts estimate a decrease in gross profit margin to 45.6% during Q1 2019 as compared to Q1 2018. However, Haemonetics is expected to report an increase in EBITDA margin during the quarter, following a decrease in the selling, general, and administrative expenses, and a decrease in research and development expenses as a percentage of sales during Q1 2019. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019 as compared to a net profit of ~$17.5 million during Q1 2018.
The SPDR S&P Health Care Equipment ETF (XHE) holds 1.6% of its total investments in Haemonetics (HAE), 1.6% in Medtronic (MDT), 1.5% in Abbott Laboratories (ABT), and 1.6% in Zimmer Biomet (ZBH).